Mereo BioPharma (MREO) Equity Ratio (2022 - 2025)
Mereo BioPharma (MREO) has disclosed Equity Ratio for 4 consecutive years, with 0.87 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio rose 206.36% to 0.87 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.87, a 206.36% increase, with the full-year FY2024 number at 0.8, up 5.02% from a year prior.
- Equity Ratio was 0.87 for Q3 2025 at Mereo BioPharma, roughly flat from 0.87 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2025 to a low of 0.82 in Q3 2024.
- A 4-year average of 0.62 and a median of 0.8 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: rose 5.02% in 2024, then soared 206.36% in 2025.
- Mereo BioPharma's Equity Ratio stood at 0.66 in 2022, then increased by 14.45% to 0.76 in 2023, then increased by 5.02% to 0.8 in 2024, then rose by 8.92% to 0.87 in 2025.
- Per Business Quant, the three most recent readings for MREO's Equity Ratio are 0.87 (Q3 2025), 0.87 (Q2 2025), and 0.88 (Q1 2025).